Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

NCT05261269 is registered in ClinicalTrials.gov with Dantari, Inc. as lead sponsor.

NCT NCT05261269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05261269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Lead sponsor
Dantari, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 2, 2022
Completion date
October 11, 2023
Enrollment
30 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative metastatic breast cancer